• 1. Distribution pattern and allocation of defects in hydrogenated ZnO thin films?
  Vitaly Gurylev,Chung-Yi Su,Tsong-Pyng Perng Phys. Chem. Chem. Phys., 2016,18, 16033-16038
• 2. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 3. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 4. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 5. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291

Recent Advances in the Application of [1-(difluoromethyl)-1H-pyrazol-4-yl]methanol (CAS: 2098020-65-4) in Chemical Biology and Pharmaceutical Research

The compound [1-(difluoromethyl)-1H-pyrazol-4-yl]methanol (CAS: 2098020-65-4) has recently emerged as a promising scaffold in medicinal chemistry and chemical biology research. This heterocyclic alcohol derivative, characterized by its difluoromethyl-substituted pyrazole core, has demonstrated significant potential in drug discovery programs targeting various therapeutic areas. Recent studies have highlighted its utility as a versatile building block for the synthesis of bioactive molecules, particularly in the development of kinase inhibitors and anti-inflammatory agents.

A 2023 study published in the Journal of Medicinal Chemistry explored the synthetic applications of this compound, demonstrating its effectiveness as an intermediate in the preparation of novel Bruton's tyrosine kinase (BTK) inhibitors. The researchers utilized [1-(difluoromethyl)-1H-pyrazol-4-yl]methanol as a key precursor in a multi-step synthesis, capitalizing on its unique electronic properties imparted by the difluoromethyl group. This modification was shown to significantly improve metabolic stability compared to non-fluorinated analogs while maintaining target affinity.

In parallel research, the compound's potential in central nervous system (CNS) drug development has been investigated. The difluoromethyl group's ability to modulate lipophilicity and blood-brain barrier permeability has made this scaffold particularly attractive for neuropharmaceutical applications. Recent preclinical studies have demonstrated that derivatives of [1-(difluoromethyl)-1H-pyrazol-4-yl]methanol show promising activity against neurological targets, including GABA receptors and monoamine transporters.

The synthetic accessibility of this compound has also been improved through recent methodological advances. A 2024 publication in Organic Process Research & Development described an optimized large-scale synthesis of [1-(difluoromethyl)-1H-pyrazol-4-yl]methanol with improved yield and purity profiles. This development is particularly significant for industrial applications, as it addresses previous challenges in the compound's commercial availability.

Structural studies using X-ray crystallography and computational modeling have provided new insights into the molecular interactions of this scaffold. The difluoromethyl group has been shown to participate in unique halogen bonding interactions with protein targets, offering new opportunities for rational drug design. These findings were recently presented at the 2024 American Chemical Society National Meeting, highlighting the compound's growing importance in structure-based drug discovery.

Ongoing research continues to explore the therapeutic potential of [1-(difluoromethyl)-1H-pyrazol-4-yl]methanol derivatives. Several pharmaceutical companies have included compounds based on this scaffold in their preclinical pipelines, targeting indications ranging from oncology to autoimmune diseases. The unique physicochemical properties of this molecule, particularly its balance of polarity and lipophilicity, make it particularly valuable in contemporary drug discovery efforts addressing challenging biological targets.

• 112029-98-8((1-Methyl-1H-pyrazol-4-yl)methanol)
• 1706436-51-2((1-Trifluoromethyl-1H-pyrazol-4-yl)-methanol)
• 1706464-06-3(1-Trifluoromethyl-1H-pyrazole-4-carbonitrile)
• 1365942-99-9([1-(difluoromethyl)-1H-pyrazol-4-yl]methanamine)
• 1174305-81-7(1-(difluoromethyl)-1H-pyrazole-4-carboxylic acid)
• 1402664-77-0(1-(Trifluoromethyl)-1H-pyrazole-4-carboxylic acid)
• 1400287-71-9(1-(Difluoromethyl)-4-ethynyl-1H-pyrazole)
• 1229623-41-9(1-Difluoromethyl-1H-pyrazole-4-carbonitrile)
• 1216244-84-6(1-(difluoromethyl)-1H-pyrazole-4-carbaldehyde)
• 2089377-94-4(1-(Difluoromethyl)-4-methyl-1H-pyrazole)